Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+Report+Publication+of+Positive+Dupilumab+Phase+2a+Data/8357210.html for the full story.
Als globales Healthcare-Unternehmen mit Niederlassungen in mehr als 100
Ländern und über 110.000 Mitarbeitern suchte Sanofi (NYSE: SNY,
EURONEXT: SAN) nach einer Möglichkeit, Prozesse zu rationalisieren und
seine...
Présent dans plus de 100 pays et comptant plus de
110 000 collaborateurs, le groupe pharmaceutique mondial Sanofi avait
besoin de simplifier ses processus et transformer son infrastructure
technologique en un réseau...
Presente in oltre 100 Paesi con più di 110.000 collaboratori, il gruppo
farmaceutico globale Sanofi (NYSE: SNY EURONEXT: SAN) desiderava
ottimizzare i propri processi interni e trasformare la sua
infrastruttura tecnologica in...
With operations in more than 100 countries and more than 110,000 staff,
global healthcare company Sanofi (NYSE: SNY EURONEXT: SAN) needed a way
to streamline processes and transform its technology infrastructure into
an...
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29+Reports+JAKARTA+Met+Primary+Endpoint+in+Both+Groups/8349866.html for the full story.
Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (CER) from the year-ago...
Oops! Unable to complete your request. Please refresh your browser.